Where Discovery, Development, and Delivery Meet
The R&D community brings together R&D, drug discovery, preclinical research, and CMC professionals from biotech, mid-sized and large pharma organizations. With a focus on cutting-edge innovations and actionable strategies, attendees will gain invaluable insights to accelerate R&D and optimize drug development and delivery.
Fierce Biotech Week 2026
May 12-14th
Early Bird Savings: Save $1,000 through March 20th
Who Will You Be Joining?
Here's a small sample of attendees:
Chief Therapeutics Officer, Eleven Therapeutics
CEO, Anvia Therapeutics
CEO, OncoSpherix
CEO, Alpha Cure Therapeutics
SVP Clinical Development, AOBiome Therapeutics
Global Operations Lead, Amgen
Scientist, AstraZeneca
Co-Founder & CEO, Axonara Biosciences
President, Blue Oaks Biotech
Founder and CEO, AgriRNA Biosciences
CEO, EnsiliTech
CEO, Cytonus Therapeutics
Director R&D IT, AbbVie
Vice President, Drug Discovery, Anvia Therapeutics
Scientific Advisor, Jeevan Therapeutics
Director, Program Management, NextPoint Therapeutics
Director II, AbbVie
Sample Operations Specialist, AstraZeneca
Scientist, AstraZeneca
Principal Research Associate, Moderna
Investor, Frist Cressey Ventures
Associate Director, Strategy & Business Insights, AbbVie / Allergan Aesthetics
Senior Director, Johnson & Johnson
Senior Director, AI Strategy & Innovation, AstraZeneca
CEO, Mitophilix
Sr. advisor, Global Business Development, GeneScience Pharmaceutical Ltd
EVP Development, Eikonizo Therapeutics
Senior Engineer II - Upstream Process Science, Takeda
Head of External Innovation, Danaher Corporation
CEO, Eos BioInnovation
Chief Manufacturing Officer, sheng cui
President & Director, EmphyCorp Pharmaceutical
CEO, EmphyCorp Pharmaceutical
Founder and CEO, Magenetic Therapeutics
Associate, Lifespan Vision Ventures
Business Development Manager, OmniBRx Biotechnologies Inc
Managing Director, Brighton Capital, Ltd.
Regulatory & PV, C4 Therapeutics Inc
SVP, Be Biopharma
Associate Director, Clinical Quality Assurance, Atea Pharmaceuticals
Senior Principal Scientist, Takeda
Sr. TMF Manager, Moderna
Director Lab and Facilities Operations, Ensoma Inc.
VP, Non-Clinical Development, Be.Bio
Data Governance & Access Lead, Takeda
Executive Director, Rome Therapeutics, LLC
Head of Boston Innovation Center, Dong-A ST
Executive Chairman, Chief Medical Officer, Adolore BioTherapeutics Inc
Director, Global Evidence and Outcomes, Takeda
CEO, AiViva BioPharma
CEO, Balinbac Therapeutics, Inc.
Exective Medical Director, Aiviva
President, Brighton Capital, Ltd.
Director Translational R&D, Curevo
Global Product & Portfolio Strategy, Ipsen
Principal Investigator/Strategic Advisor, 3X Genetics Inc.
Associate Director, Immunology, Orum Therapeutics
CEO, Lamassu Biotech
CSO, Lamassu Biotech
President & CMO, Infinitopes
Chief Clinical Development Officer, Kartos Therapeutics
Principal Scientist, Sanofi
Postdoctoral Fellow in drug delivery, Harvard University
Founder, XAIGene Biotechnology
CEO, Immuto Scientific
Global Head of DE&I, Takeda Pharmaceutical
Executive Director, NewHyll Therapeutics
Chairman of the Board, BioFactura, Inc.
CSO, Centauri Therapeutics
Sr Advisor, GATC Health Corp
CFO, Mind Pharmaceuticals
BD, DomaBio
Director of Operations, Regeneron
Founder, Nutraponia Therapeutics
Head of R&D Alliances, Astellas Pharma Inc.
Director, BMS
CEO, NovaSpira Biotherapeutics Inc.
CEO, POP TEST ONCOLOGY LLC
CEO, miRecule, Inc.
Product Strategy Lead, Takeda
CEO, Aanastra Inc
Therapeutics Division Lead, General Inception
Director CMC, Gemma Biotherapeutics
CTO, RephImmune
CEO, Attivare Therapeutics
Vice President of R&D, Cathedral Therapeutics
RD Program Management Excellence, BuoNTech SE
Owner, AK investment
Chief Scientific Officer, Cellarity
Consultant, Tessera Therapeutics
Digital Excellence Lead, Johnson & Johnson
Sr. Director, Formulation Sciences, Blueprint Medicines, a Sanofi Company
Manager of Data Engineer Evidence Generation, Daiichi Sankyo
Director, Biology, Tesseract Medicines
Co-founder & Board member, Clover Key Bioscience
Senior Staff Engineer, Takeda
Director, Corporate Counsel, Otsuka America Pharmaceuticals, Inc.
General Counsel, Seaport Therapeutics
CBO, Envisagenics
Director of Business Development, Envisagenics
Principal Scientist II, Gilead Sciences Inc
Lead, R&D Alliances, Astellas
Senior Director, Sanofi
CEO, Infiltrate Bio
CEO, CRI Biotech Inc.
Process Scientist, TG Therapeutics
Managing Partner, Rosetta Capital Ltd
Director, Alnylam
CEO, Model Medicines
CEO, Angiotensin Therapeutics
CFO, MetaVia Inc
Chief Research and Development Officer, Azura Ophthalmics
Director, Atommap
Principal Scientist, Atommap
Senior R&D Engineer, Roche Diabetes Care GmbH
CEO and Co-Founder, Cellular Life Sciences, Inc.
Head of CMC, Skye Bioscience
CEO, Vardhaya
Sr Director, Research, Obsidian Therapeutics
Clinical Scientist, Alnylam
Scientific Director, quadraScope Ventures
Chief Executive Officer, Hanall Biopharma
Senior Expert, CGT, Novartis
Director, AbbVie
CEO, Sterling Financial
CBO, Co-founder, Exhaura, Inc.
Sr Director, Product Innovation, Flagship Pioneering
VP Head of Late Discovery, Jnana Therapeutics
CEO, LEON Nanodrugs
Partner, Vectors Capital
Associate Director, Magnet Biomedicine
Vice President, Head of Clinical Science, Cullinan Therapeutics
President & CEO, GlycoMantra Inc.
Director Strategy Insights and Analytics, Ultragenyx
SVP Finance, Mathew Lindenmayer
CEO, Micron Biomedical
Business Development Manager, Terumo Blood and Cell Technologies
CEO, IMMEDIATE TX
CEO, Pro-Al Medico Technologies, Inc.
President / COO, Flow Pharma, Inc
Associate Director, Procurement & Strategic Sourcing, Amylyx Pharmaceuticals, Inc.
Senior Director, Procurement & Strategic Sourcing, Amylyx Pharmaceuticals, Inc.
Director, Business Planning & Operations, AstraZeneca
CEO, Myris Therapeutics
VP, Alnylam
Executive VP of Research, Myris Therapeutics
Chief Development Officer, ModeX
What’s Next for the Pipeline
Strategic conversations on advancing innovation, securing investment, and delivering impact from discovery to development.
Topics covered in the R&D track:
From Agentic AI to Regulatory Credibility
R&D in a Capital-Disciplined Market
Why Manufacturing Readiness Is Now a Leadership Issue
Why Most Immuno-Oncology Programs Fail & What the Next Winners Are Doing Differently
Building Companies at the Frontiers of Science
